Top

BMC Geriatrics

Published in:

Open Access 01-12-2022 | Proton Pump Inhibitors | Research

Prescribing trends of proton pump inhibitors, antipsychotics and benzodiazepines of medicare part d providers

Authors: Jennifer M. Toth, Saumil Jadhav, Holly M. Holmes, Manvi Sharma

Published in: BMC Geriatrics | Issue 1/2022

Abstract

Background

Proton pump inhibitors, benzodiazepines, and antipsychotics are considered potentially inappropriate medications in older adults according to the American Geriatric Society Beers Criteria, and deprescribing algorithms have been developed to guide use of these drug classes. The objective of this study was to describe the number of beneficiaries prescribed these medications, provider specialty and regional trends in prescribing, and the aggregate costs for these claims in Medicare Part D.

Methods

This was a retrospective cross-sectional study using publicly available Medicare Provider Utilization and Payment Data: Part D Prescriber data for years 2013–2019. Descriptive statistics and the Cochrane-Armitage test were used to summarize the trends.

Results

Overall, 30.1%, 25.6%, 4.6% of Medicare Part D beneficiaries had a proton pump inhibitor, benzodiazepine, and antipsychotic claim in 2013, respectively. These rates decreased to 27.5%, 17.5%, 4.1% in 2019 (p-value < 0.0001). However, the number of standardized 30-day claims increased from 63 million in 2013 to 84 million in 2019 for proton pump inhibitors, remained steady for benzodiazepines and slightly increased (10 million to 13 million) for antipsychotics. Total aggregate costs decreased by almost $1.5 billion for proton pump inhibitor, $100 million for benzodiazepine, and $700 million for antipsychotic from 2013 to 2019 (p-value < 0.0001). Almost 93% of gastroenterologists prescribed a proton pump inhibitor, and 60% of psychiatrists prescribed benzodiazepines and antipsychotics all seven years. The Other region had the highest percentage of providers prescribing all three classes and the highest number of standardized 30-day benzodiazepine claims.

Conclusions

The overall rate of use of proton pump inhibitors, benzodiazepines, and antipsychotics decreased from 2013–2019 among Medicare Part D beneficiaries. Despite the increase in raw number of standardized 30-day claims, the costs decreased which is likely due to generics made available. These prescribing trends may aid in identifying and targeting potential deprescribing interventions.

American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674–94. https://doi.org/10.1111/jgs.15767.

Farrell B, Pottie K, Thompson W, et al. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Physician. 2017;63(5):354–64.PubMedPubMedCentral

Bjerre LM, Farrell B, Hogel M, et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: evidence-based clinical practice guideline. Can Fam Physician. 2018;64(1):17–27.PubMedPubMedCentral

Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline. Can Fam Physician. 2018;64(5):339–51.PubMedPubMedCentral

Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827–34. https://doi.org/10.1001/jamainternmed.2015.0324.CrossRefPubMed

Kanno T, Moayyedi P. Proton pump inhibitors in the elderly, balancing risk and benefit: an age-old problem. Curr Gastroenterol Rep. 2019;21(12):65. https://doi.org/10.1007/s11894-019-0732-3.CrossRefPubMed

Yunusa I, Alsumali A, Garba AE, Regestein QR, Eguale T. Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia. JAMA Netw Open. 2019;2(3): e190828. https://doi.org/10.1001/jamanetworkopen.2019.0828.CrossRefPubMedPubMedCentral

Zarowitz BJ, Allen C, O’Shea T, Strauss ME. Risk factors, clinical characteristics, and treatment differences between residents with and without nursing home- and non-nursing home-acquired clostridium difficile infection. J Manag Care Spec Pharm. 2015;21(7):585–95. https://doi.org/10.18553/jmcp.2015.21.7.585.CrossRefPubMed

Zacharioudakis IM, Zervou FN, Shehadeh F, Mylona EK, Mylonakis E. Association of community factors with hospital-onset Clostridioides (Clostridium) difficile infection: a population based U.S.-wide study. EClinicalMedicine. 2019;8:12–9. https://doi.org/10.1016/j.eclinm.2019.02.001.CrossRefPubMedPubMedCentral

10.

Emeny RT, Chang CH, Skinner J, et al. Association of receiving multiple, concurrent fracture-associated drugs with hip fracture risk. JAMA Netw Open. 2019;2(11):e1915348. https://doi.org/10.1001/jamanetworkopen.2019.15348.CrossRefPubMedPubMedCentral

11.

Munson JC, Bynum JP, Bell JE, et al. Impact of prescription drugs on second fragility fractures among US medicare patients. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2018;29(12):2771–9. https://doi.org/10.1007/s00198-018-4697-0.CrossRef

12.

Ding J, Heller DA, Ahern FM, Brown TV. The relationship between proton pump inhibitor adherence and fracture risk in the elderly. Calcif Tissue Int. 2014;94(6):597–607. https://doi.org/10.1007/s00223-014-9855-6.CrossRefPubMed

13.

Stockl KM, Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med. 2010;170(8):704–10. https://doi.org/10.1001/archinternmed.2010.34.CrossRefPubMed

14.

Lee SW, Ha EK, Yeniova AÖ, et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut. 2021;70(1):76–84. https://doi.org/10.1136/gutjnl-2020-322248.CrossRefPubMed

15.

Schubert ML. Proton pump inhibitors: misconceptions and proper prescribing practice. Curr Opin Gastroenterol. 2020;36(6):493–500. https://doi.org/10.1097/MOG.0000000000000676.CrossRefPubMed

16.

Abraham NS, Castillo DL, Hartman C. National mortality following upper gastrointestinal or cardiovascular events in older veterans with recent nonsteroidal anti-inflammatory drug use. Aliment Pharmacol Ther. 2008;28(1):97–106. https://doi.org/10.1111/j.1365-2036.2008.03706.x.CrossRefPubMed

17.

Abraham NS, Hartman C, Hasche J. Reduced hospitalization cost for upper gastrointestinal events that occur among elderly veterans who are gastroprotected. Clin Gastroenterol Hepatol. 2010;8(4):350–6. https://doi.org/10.1016/j.cgh.2010.01.002.CrossRefPubMed

18.

Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton-pump-inhibitor co-therapy with hospitalization for upper gastrointestinal bleeding. JAMA. 2018;320(21):2221–30. https://doi.org/10.1001/jama.2018.17242.CrossRefPubMedPubMedCentral

19.

Ray WA, Chung CP, Murray KT, et al. Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding. Gastroenterology. 2016;151(6):1105-1112.e10. https://doi.org/10.1053/j.gastro.2016.08.054.CrossRefPubMed

20.

Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry. 2012;169(9):900–6. https://doi.org/10.1176/appi.ajp.2012.12030342.CrossRefPubMedPubMedCentral

21.

Neufeld KJ, Yue J, Robinson TN, Inouye SK, Needham DM. Antipsychotics for prevention and treatment of delirium in hospitalized adults: a systematic review and meta-analysis. J Am Geriatr Soc. 2016;64(4):705–14. https://doi.org/10.1111/jgs.14076.CrossRefPubMedPubMedCentral

22.

Seppala LJ, Wermelink AMAT, de Vries M, et al. Fall-risk-increasing drugs: a systematic review and meta-analysis: II. Psychotropics J Am Med Dir Assoc. 2018;19(4):371.e11-371.e17. https://doi.org/10.1016/j.jamda.2017.12.098.CrossRef

23.

Markota M, Rummans TA, Bostwick JM, Lapid MI. Benzodiazepine use in older adults: dangers, management, and alternative therapies. Mayo Clin Proc. 2016;91(11):1632–9. https://doi.org/10.1016/j.mayocp.2016.07.024.CrossRefPubMed

24.

Gawron AJ, Feinglass J, Pandolfino JE, Tan BK, Bove MJ, Shintani-Smith S. Brand Name and Generic Proton Pump Inhibitor Prescriptions in the United States: Insights from the National Ambulatory Medical Care Survey (2006–2010). Gastroenterol Res Pract. 2015;2015. Article ID 689531, 7 pages. https://doi.org/10.1155/2015/689531

25.

Pham CQ, Regal RE, Bostwick TR, Knauf KS. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother. 2006;40(7–8):1261–6. https://doi.org/10.1345/aph.1G703.CrossRefPubMed

26.

Leri F, Ayzenberg M, Voyce SJ, Klein A, Hartz L, Smego RA. Four-year trends of inappropriate proton pump inhibitor use after hospital discharge. South Med J. 2013;106(4):270–3. https://doi.org/10.1097/SMJ.0b013e31828db01f.CrossRefPubMed

27.

Thomas L, Culley EJ, Gladowski P, Goff V, Fong J, Marche SM. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm. 2010;16(2):122–9. https://doi.org/10.18553/jmcp.2010.16.2.122.CrossRefPubMed

28.

Lind KE, Raban MZ, Georgiou A, Westbrook JI. Duration of antipsychotic medication use by aged care facility residents with dementia. Alzheimer Dis Assoc Disord. 2019;33(4):331–8. https://doi.org/10.1097/WAD.0000000000000336.CrossRefPubMed

29.

Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiat. 2015;72(2):136–42.CrossRef

30.

Neutel CI, Skurtveit S, Berg C. What is the point of guidelines? Benzodiazepine and z-hypnotic use by an elderly population. Sleep Med. 2012;13(7):893–7. https://doi.org/10.1016/j.sleep.2011.12.014.CrossRefPubMed

31.

Medicare Provider Utilization and Payment Data: Part D Prescriber | CMS. Updated December 1, 2021. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Part-D-Prescriber. Accessed 4 Apr 2022.

32.

The Centers for Medicare & Medicaid Services, Office of Enterprise Data and Analytics. Medicare Fee-For Service Provider Utilization & Payment Data Part D Prescriber Public Use File: A Methodological Overview. Published online November 6, 2020. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Downloads/Prescriber_Methods.pdf. Accessed 4 Mar 2022.

33.

Medicare Part D Prescribers - by Provider and Drug Data Dictionary - Centers for Medicare & Medicaid Services Data. Updated August 25, 2021. https://data.cms.gov/resources/medicare-part-d-prescribers-by-provider-and-drug-data-dictionary. Accessed 4 Mar 2022.

34.

US Census Bureau. 2010 Census Regions and Divisions of the United States. Census.gov. Updated October 8, 2021. https://www.census.gov/geographies/reference-maps/2010/geo/2010-census-regions-and-divisions-of-the-united-states.html. Accessed 4 Mar 2022.

35.

Rane PP, Guha S, Chatterjee S, Aparasu RR. Prevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the US. Res Soc Adm Pharm. 2017;13(2):358–63. https://doi.org/10.1016/j.sapharm.2016.02.012.CrossRef

36.

Schneeweiss S, Patrick AR, Pedan A, et al. The effect of medicare part d coverage on drug use and cost sharing among seniors without prior drug benefits. Health Aff Proj Hope. 2009;28(2):w305–16. https://doi.org/10.1377/hlthaff.28.2.w305.CrossRef

37.

Shrank WH, Patrick AR, Pedan A, et al. The effect of transitioning to medicare part d drug coverage in seniors dually eligible for medicare and medicaid. J Am Geriatr Soc. 2008;56(12):2304–10. https://doi.org/10.1111/j.1532-5415.2008.02025.x.CrossRefPubMedPubMedCentral

38.

Gray N. Teva wins big as FDA approves its generic Nexium. BioPharma Dive. Published January 27, 2015. Accessed July 16, 2020. https://www.biopharmadive.com/news/teva-wins-big-as-fda-approves-its-generic-nexium/357098/

39.

New Drug Application (NDA): 204655. Drugs@FDA: FDA-Approved Drugs. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204655. Accessed 17 Feb 2021.

40.

2017 First Generic Drug Approvals. FDA. Updated February 20, 2018. https://www.fda.gov/drugs/first-generic-drug-approvals/2017-first-generic-drug-approvals. Accessed 16 July 2020.

41.

Strand DS, Kim D, Peura DA. 25 Years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11(1):27–37. https://doi.org/10.5009/gnl15502.CrossRefPubMed

42.

Luetzenberg FS, Jiang N. Practice patterns of reflux medication prescriptions in otolaryngology compared to other specialties. Laryngoscope. 2020;130(2):321–7. https://doi.org/10.1002/lary.27916.CrossRefPubMed

43.

Pan K, Silver S, Davis C, Pan K, Silver S, Davis C. Analysis of psychiatrists’ prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States. Trends Psychiatry Psychother. 2020;42(1):48–54. https://doi.org/10.1590/2237-6089-2019-0015.CrossRefPubMed

44.

Campanelli CM. American geriatrics society updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616–31. https://doi.org/10.1111/j.1532-5415.2012.03923.x.CrossRefPubMedCentral

45.

Gray E, Bradley B. Evaluation of the prescribing practices of nonbenzodiazepine, benzodiazepine receptor agonist hypnotics in adults at a federally qualified health center. J Am Pharm Assoc (2003). 2019;59(4S):S146–50. https://doi.org/10.1016/j.japh.2019.05.006.

46.

FDA approves first generic Abilify. Formulary Watch. 2015. https://www.formularywatch.com/view/fda-approves-first-generic-abilify. Accessed 19 Feb 2021.

47.

Intellipharmaceutics International Inc. Intellipharmaceutics Announces FDA Tentative Approval for Generic Seroquel XR®. GlobeNewswire News Room. Published October 7, 2016. http://www.globenewswire.com/news-release/2016/10/07/878050/0/en/Intellipharmaceutics-Announces-FDA-Tentative-Approval-for-Generic-Seroquel-XR.html. Accessed 19 Feb 2021.

48.

Chen H, Nwangwu A, Aparasu R, Essien E, Sun S, Lee K. The impact of medicare part d on psychotropic utilization and financial burden for community-based seniors. Psychiatr Serv. 2008;59(10):1191–7. https://doi.org/10.1176/ps.2008.59.10.1191.CrossRefPubMed

49.

Avraham O, Biglow M. Implementation of proton pump inhibitor deprescription protocol in geriatric residents. Ann Pharmacother. 2018;52(8):747–53. https://doi.org/10.1177/1060028018759747.CrossRefPubMed

50.

Odenthal DR, Philbrick AM, Harris IM. Successful deprescribing of unnecessary proton pump inhibitors in a primary care clinic. J Am Pharm Assoc. 2020;60(1):100–4. https://doi.org/10.1016/j.japh.2019.08.012.CrossRef

51.

Wilsdon TD, Hendrix I, Thynne TRJ, Mangoni AA. Effectiveness of interventions to deprescribe inappropriate proton pump inhibitors in older adults. Drugs Aging. 2017;34(4):265–87. https://doi.org/10.1007/s40266-017-0442-1.CrossRefPubMed

52.

Conn DK, Hogan DB, Amdam L, et al. Canadian guidelines on benzodiazepine receptor agonist use disorder among older adults. Can Geriatr J. 2020;23(1):116–22. https://doi.org/10.5770/cgj.23.419.CrossRefPubMedPubMedCentral

53.

Vicens C, Bejarano F, Sempere E, et al. Comparative efficacy of two interventions to discontinue long-term benzodiazepine use: cluster randomised controlled trial in primary care. Br J Psychiatry. 2014;204(6):471–9. https://doi.org/10.1192/bjp.bp.113.134650.CrossRefPubMed

54.

Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: The EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174(6):890. https://doi.org/10.1001/jamainternmed.2014.949.CrossRefPubMed

55.

Pan YJ, Wu CS, Gau SSF, Chan HY, Banerjee S. Antipsychotic discontinuation in patients with dementia: a systematic review and meta-analysis of published randomized controlled Studies. Dement Geriatr Cogn Disord. 2014;37(3–4):125–40. https://doi.org/10.1159/000355418.CrossRefPubMed

Title: Prescribing trends of proton pump inhibitors, antipsychotics and benzodiazepines of medicare part d providers
Authors: Jennifer M. Toth
Saumil Jadhav
Holly M. Holmes
Manvi Sharma
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Proton Pump Inhibitors
Antipsychotics
Antipsychotics
Benzodiazepine
Published in: BMC Geriatrics / Issue 1/2022
Electronic ISSN: 1471-2318
DOI: https://doi.org/10.1186/s12877-022-02971-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Incidence and type of restrictive practice use in nursing homes in Ireland

Equipment-free, unsupervised high intensity interval training elicits significant improvements in the physiological resilience of older adults

Elicitation of quantitative, choice-based preferences for Person-Centered Care among People living with Dementia in comparison to physicians’ judgements in Germany: study protocol for the mixed-methods PreDemCare-study

Protocol for a mixed-methods and multi-site assessment of the implementation process and outcomes of a new community-based frailty programme

Community-based mental health and well-being interventions for older adults in low- and middle-income countries: a systematic review and meta-analysis

Trends in utilisation of plain X-rays by older Australians (2010–2019)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials